This folder covers DRG’s Company & Drugs (C&D) data for Anti-infective which include market forecast (US, ROW and Global) and analysis on drug profile, drug group and therapy area.
Parkinson’s disease (PD) is widely recognized as a motor disorder, but PD is also associated with a diverse set of nonmotor symptoms. Surveyed neurologists estimate that 20% of their PD patients…
Immune checkpoint inhibitors have transformed the treatment algorithm for recurrent or metastatic non-nasopharyngeal squamous cell carcinoma of the head and neck (SCCHN) and diversified treatment…
Tourette syndrome is a neurological disorder characterized by repetitive, uncontrollable movements and/or unwanted vocal sounds (tics) and typically begins in childhood. Tics range from mild to…
DRG Epidemiology’s coverage of endometriosis comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets. We report both the diagnosed…
DRG Epidemiology’s coverage of endometriosis comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report both the…
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range of clinical symptoms, from general fatigue to serious…
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range of clinical symptoms, from general fatigue to serious…
Chronic low back pain (CLBP), defined as continuous low back pain lasting for at least three months, represents the largest segment of the chronic pain therapy market. Prescription treatment…
Novartis’s Beovu (brolucizumab-dbll) is the fourth vascular endothelial growth factor (VEGF) inhibitor to launch for the treatment of wet age-related macular degeneration (AMD) in the United…
The moderate to severe atopic dermatitis (AD) market is at the beginning of a revolution with the recent approval of Sanofi/Regeneron’s first-in-class biologic, Dupixent, and a promising suite of…
DRG Epidemiology's coverage of rheumatoid arthritis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of rheumatoid…
DRG Epidemiology’s coverage of Sjögren’s syndrome (SS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and…
DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key rheumatoid arthritis patient populations covering 171 countries and more…
DRG Epidemiology’s coverage of Sjögren’s syndrome (SS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and…